• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Does TMS Really Work in Depression?

Does TMS Really Work in Depression?

November 1, 2018
Michael Posternak, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Michael Posternak, MD Dr. Posternak has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review of: Yesavage et al, JAMA Psychiatry 2018;75(9):884–893

Type of study: Randomized, sham-controlled trial

Repetitive transcranial magnetic stimulation (rTMS) has been FDA-approved for treatment-resistant depression (TRD) since 2008. This non-invasive therapy uses an electromagnetic coil to stimulate electrical activity in the frontal cortex. The present study tested its efficacy in a VA population of TRD patients with complex comorbidities.

This was a double-blind, sham-controlled, randomized trial conducted across 9 VA medical centers. In total, 164 subjects were enrolled; the average age was 55, and 81% were men. Treatment resistance was defined as 2 or more failed adequate antidepressant trials. Subjects had high rates of comorbidity, including PTSD (49%), medical comorbidity (49%), and a history of substance abuse (54%). Most were poorly functioning: Only 24% were working, and only 38% were married.

rTMS and sham rTMS were delivered for up to 30 sessions. Both groups came for treatment 5 days a week. Importantly, the sessions included supportive elements such as daily queries of mood and medication adherence and weekly screening for substance use. The primary outcome was remission of depression (≤ 10 on the Hamilton Depression Rating Scale).

rTMS displayed no advantage over sham treatment on the primary measure. Specifically, 41% achieved remission with active treatment, compared to 37% with sham treatment (p = .67). A sub-analysis suggested that rTMS might be more effective for depressed patients without comorbid PTSD (49% vs 43% remission rates), though this difference did not reach statistical significance either (p = .09). rTMS was very well-tolerated.

TCPR’s Take
Does this mean rTMS does not work? Not exactly, but it offered little benefit in this population of predominantly low-functioning men with complex comorbidities in the VA system. Remission rates were unusually high in both groups, and the fact that 40% recovered with the sham speaks to the therapeutic value of behavioral activation, structure, and social interaction in overcoming even the most seemingly refractory depressions. When all the studies are considered, ECT is more effective than rTMS and should be first-line when depression has not responded to traditional pharmacotherapy (Chen JJ, Behav Brain Res 2017;320:30–36).
General Psychiatry
KEYWORDS depressive_disorder free_articles research-update
    Michael Posternak, MD

    Moderate Alcohol Use Associated With Reduced Risk of Dementia

    More from this author
    www.thecarlatreport.com
    Issue Date: November 1, 2018
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Drug Metabolism, TCPR, November/December 2018
    New Approvals for TMS
    Is Clozapine the Next Step After a Single Failed Antipsychotic Trial?
    Does TMS Really Work in Depression?
    Probiotics for Bipolar Disorder
    Ask the Editor: Which Antipsychotic Is Best When Patients Complain of Akathisia?
    Effects of Drug Interactions
    Harnessing Beneficial Drug Interactions
    New Stimulants: From Remixed Amphetamines to Bedtime Ritalin
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.